Asoprisnil_ecamate

Asoprisnil ecamate

Asoprisnil ecamate

Chemical compound

Asoprisnil ecamate (INN) (developmental code name J-956) is a synthetic, steroidal selective progesterone receptor modulator (SPRM) which was under development for the treatment of endometriosis, uterine fibroids, and menopausal symptoms but was discontinued.[1][2][3] It is a potent and highly selective ligand of the progesterone receptor with mixed agonistic and antagonistic activity and much reduced antiglucocorticoid activity relative to mifepristone.[2][3][4] The drug reached phase III clinical trials for the aforementioned indications prior to its discontinuation.[1]

Quick Facts Clinical data, Other names ...

See also

References

  1. [1]
    "Asoprisnil - AdisInsight".
  2. [2]
    Schubert G, Elger W, Kaufmann G, Schneider B, Reddersen G, Chwalisz K (2005). "Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11beta-benzaldoxime substituted selective progesterone receptor modulators (SPRMs)". Seminars in Reproductive Medicine. 23 (1): 58–73. doi:10.1055/s-2005-864034. PMID 15714390. S2CID 260316786.
  3. [3]
    Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W (2005). "Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis". Endocrine Reviews. 26 (3): 423–38. doi:10.1210/er.2005-0001. PMID 15857972.
  4. [4]
    Chwalisz K, Garg R, Brenner R, Slayden O, Winkel C, Elger W (2006). "Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs)". Reproductive Biology and Endocrinology. 4 (Suppl 1): S8. doi:10.1186/1477-7827-4-S1-S8. PMC 1775068. PMID 17118172.
Stub icon

This article about a steroid is a stub. You can help Wikipedia by expanding it.

Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Asoprisnil_ecamate, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.